These discrepancies might be related to various factors, e.g., different demographic features (i.e., sample size and race), CRC stage (early or advanced), different antibodies of anti-ARID1A, the assessments of the ARID1A protein expression (i.e., IHC, western blot, targeted sequencing analysis, qRT-PCR, tissue microarrays, and chromatin immunoprecipitation), and multifarious co-present or targeted genes being affected. Here, ARID1A is linked to colorectal carcinoma.